PTC Therapeutics (PTCT) Stock Looks About Right At This Price

PTC Therapeutics has had a mixed run recently, with the stock down over shorter time frames but still showing a very strong 3 year gain. That puts a spotlight on whether the current share price makes sense compared with the revenue the business is generating. For investors, the central issue is how much of that share price is really being backed by its sales line rather than just sentiment around the pipeline.

• Over the past 3 years, PTC Therapeutics has returned about 191.1% which means anyone looking at the stock today needs to ask how closely that performance lines up with its underlying sales power.
• The company relies heavily on monetizing a focused set of rare disease therapies, so future sales can hinge on execution in a small set of markets and that concentration can matter a lot when you are trying to judge what each dollar of revenue should be worth.
• Your read on PTC Therapeutics is one view; the desks covering it have another. See what analysts think PTC Therapeutics's shares could be worth.

The issue now is whether PTC Therapeutics' recent share price near US$59.67 is appropriately supported by its sales when set against the Fair Ratio yardstick.

If you are weighing whether PTC Therapeutics' recent run really lines up with its sales, it can help to compare that setup with 32 high quality undervalued stocks

Is PTC Therapeutics Fairly Priced on Sales?

The P/S ratio suits PTC Therapeutics because investors often focus on revenue for biotech firms that are still working toward consistent profits. On this yardstick, the stock trades at about 4.9x sales, which sits below the broader biotechs sector average of 10.9x and also under the closer peer group on roughly 6.1x.

The Fair Ratio framework, which looks at factors like growth potential, margins, scale and risk, points to a P/S level close to where PTC Therapeutics currently trades. That keeps the multiple in a zone that looks about right on this model, so the key question for you is whether the rare disease portfolio justifies paying this kind of sales multiple over time. Explore the numbers behind PTC Therapeutics's P/S valuation.

The PTC Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for PTC Therapeutics pick up where the P/S work leaves off. They spell out which paths for future growth, profitability and earnings power would need to hold for the stock to be worth far more or far less than today’s price, and turn a single ratio output into a set of concrete assumptions you can watch over time on the Community page.

One of the top community narratives on PTC Therapeutics: 56% undervalued

"The main thing that has to go right is continued execution on Sephience and new rare disease launches, including ST-920 and late-stage neurology programs…"

Discover why this Narrative puts PTC Therapeutics at 56% undervalued.

One more PTC Therapeutics check that belongs beside the sales multiple

Price ratios only tell part of the story, because recent share disposals by people inside the business can add a different kind of signal for you to unpack. See the recent insider selling flagged for PTC Therapeutics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com